You are here

Integrated Digital PCR Platform with a Micromolded Siphoning Array

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43OD023028-01
Agency Tracking Number: R43OD023028
Amount: $700,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 100
Solicitation Number: PA15-052
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-06-15
Award End Date (Contract End Date): 2018-05-31
Small Business Information
3436 RAMBOW DR
Palo Alto, CA 94306-3638
United States
DUNS: 080013010
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PAUL HUNG
 (510) 703-6887
 paul.hung@combinati.com
Business Contact
 PAUL HUNG
Phone: (510) 703-6887
Email: paul.hung@combinati.com
Research Institution
N/A
Abstract

Abstract
Combinati is looking to bring an integrated digital PCR platform with injection molded microfluidic
consumables from lab to marketplace to advance the biomedical research Digital PCR has drawn
attentions in both genomic research and clinical research communities for its ability to detect rare
events high sensitivity less prone to inhibition high specificity no need for an internal standard high
precision and access to well developed PCR reagents However current dPCR instruments are capital
intensive cost per sample is high and the workflow is complicated The year Phase SBIR project will
allow Combinati to complete the validation of the following key value hypothesis which will serve as the
new product design spec for Phase commercialization effort
Combinati s unique consumable technology allows high density reagent digitization on a
standard format using a scalable manufacturing process
The industry standard format allows integration of pneumatics thermal optical and software
modules into one benchtop instrument to offer significant workflow advantage over current
commercially available products
Off the shelf PCR reagents are compatible with the platform without purchasing of specialized
reagents Narrative
There are increasing evidences showing that nucleic acids could complement proteins as additional
biomarkers when it comes to disease prevention prognosis diagnosis as well as therapeutics efficacy
monitoring Combinati is developing a precision nucleic acid quantification platform in the hope to
accelerate the adoption of dPCR technology in the genomic research market and catalyze its transition
from benchtop to bedside With the help from this Phase SBIR project we will prove the feasibility of
an integrated digital PCR dPCR platform with the best combination of workflow easiness cost sample
throughput run and performance experiment

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government